Dehydrocrenatine is primarily used in pharmaceutical research due to its potential bioactive properties. It has shown interest in neurological studies for its possible modulatory effects on neurotransmitter systems, particularly those involving dopamine and serotonin pathways. This makes it a candidate for exploring treatments related to neurodegenerative disorders and mood-related conditions. Additionally, dehydrocrenatine serves as a chemical intermediate in the synthesis of more complex alkaloid derivatives, aiding in the development of novel therapeutic agents. Its structural characteristics also support its use in structure-activity relationship (SAR) studies, helping researchers optimize alkaloid-based drug designs.